Who is sponsoring NCT00426127?

NCT00426127 is sponsored by University of Iowa.

What condition does NCT00426127 study?

NCT00426127 studies Pancreatic Cancer.

What drugs are being tested in NCT00426127?

Interventions: Docetaxel, Liposomal Doxorubicin, Enoxaparin.

What is the status of NCT00426127?

NCT00426127 is currently TERMINATED.

Last reviewed 2017-12-05 · How we verify

Phase II Trial of Docetaxel and Liposomal Doxorubicin (Doxil) Chemotherapy Combined With Enoxaparin in Patients With Advanced Pancreatic Cancer

NCT00426127 Phase 2 TERMINATED Results posted

The purpose of this study is to assess the effects of the treatment combination of the commercially available chemotherapy drugs, docetaxel and liposomal doxorubicin, and a blood thinner Enoxaparin on pancreatic cancer. The main goal of the study is to find out if this combination chemotherapy and enoxaparin increases the number of individuals whose tumors shrink.

Details

Lead sponsor	University of Iowa
Phase	Phase 2
Status	TERMINATED
Enrolment	2
Start date	2006-11
Completion	2009-08

Conditions

Pancreatic Cancer

Interventions

Docetaxel
Liposomal Doxorubicin
Enoxaparin

Primary outcomes

Tumor Response Measured by CT Scans After Each Set of 3 Cycles of Chemotherapy — 9 weeks

Countries

United States